{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:21:29Z","timestamp":1788315689751,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UC4DK108611"],"award-info":[{"award-number":["UC4DK108611"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UC4DK108611"],"award-info":[{"award-number":["UC4DK108611"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11892-019-1177-7","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T09:17:35Z","timestamp":1561627055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Advanced Technology in the Management of Diabetes: Which Comes First\u2014Continuous Glucose Monitor or Insulin Pump?"],"prefix":"10.1007","volume":"19","author":[{"given":"Christopher T.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Criego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders L.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"issue":"12","key":"1177_CR1","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/clinchem\/48.12.2270","volume":"48","author":"L Rosenfeld","year":"2002","unstructured":"Rosenfeld L. Insulin: discovery and controversy. Clin Chem. 2002;48(12):2270\u201388.","journal-title":"Clin Chem"},{"issue":"2","key":"1177_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1056\/NEJMra040832","volume":"352","author":"IB Hirsch","year":"2005","unstructured":"Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174\u201383.","journal-title":"N Engl J Med"},{"issue":"14","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med"},{"key":"1177_CR4","doi-asserted-by":"crossref","unstructured":"Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18(3):361\u2013376.","DOI":"10.2337\/diacare.18.3.361"},{"issue":"Suppl 1","key":"1177_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00592-009-0132-5","volume":"47","author":"M Monami","year":"2010","unstructured":"Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010;47(Suppl 1):77\u201381.","journal-title":"Acta Diabetol"},{"issue":"10","key":"1177_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1046\/j.1464-5491.2003.01018.x","volume":"20","author":"J Colquitt","year":"2003","unstructured":"Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med. 2003;20(10):863\u20136.","journal-title":"Diabet Med"},{"issue":"7","key":"1177_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1464-5491.2008.02486.x","volume":"25","author":"JC Pickup","year":"2008","unstructured":"Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765\u201374.","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"1177_CR8","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/dmrr.205","volume":"18","author":"BW Bode","year":"2002","unstructured":"Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18(Suppl 1):S14\u201320.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dsx.2017.09.005","volume":"12","author":"D Olczuk","year":"2018","unstructured":"Olczuk D, Priefer R. A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus. Diabetes Metab Syndr. 2018;12(2):181\u20137.","journal-title":"Diabetes Metab Syndr"},{"issue":"12","key":"1177_CR10","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.2337\/db13-1132","volume":"62","author":"A Basu","year":"2013","unstructured":"Basu A, Dube S, Slama M, Errazuriz I, Amezcua JC, Kudva YC, et al. Time lag of glucose from intravascular to interstitial compartment in humans. Diabetes. 2013;62(12):4083\u20137.","journal-title":"Diabetes."},{"issue":"1","key":"1177_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/1932296814554797","volume":"9","author":"A Basu","year":"2015","unstructured":"Basu A, Dube S, Veettil S, Slama M, Kudva YC, Peyser T, et al. Time lag of glucose from intravascular to interstitial compartment in type 1 diabetes. J Diabetes Sci Technol. 2015;9(1):63\u20138.","journal-title":"J Diabetes Sci Technol"},{"key":"1177_CR12","first-page":"CD008101","volume":"1","author":"M Langendam","year":"2012","unstructured":"Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2012;1:CD008101.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1177_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3390\/s16122093","volume":"16","author":"Andrea Facchinetti","year":"2016","unstructured":"Facchinetti A. Continuous glucose monitoring sensors: past, present and future algorithmic challenges. Sensors (Basel). 2016;16(12).","journal-title":"Sensors"},{"issue":"1","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1932296816662047","volume":"11","author":"F Reiterer","year":"2017","unstructured":"Reiterer F, Polterauer P, Schoemaker M, Schmelzeisen-Redecker G, Freckmann G, Heinemann L, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol. 2017;11(1):59\u201367.","journal-title":"J Diabetes Sci Technol"},{"issue":"9\u201312","key":"1177_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0956-5663(01)00189-0","volume":"16","author":"MJ Tierney","year":"2001","unstructured":"Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S, Team CR. Clinical evaluation of the GlucoWatch biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron. 2001;16(9\u201312):621\u20139.","journal-title":"Biosens Bioelectron"},{"issue":"3","key":"1177_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/dia.2014.0272","volume":"17","author":"BP Kovatchev","year":"2015","unstructured":"Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther. 2015;17(3):177\u201386.","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"1177_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc16-2482","volume":"40","author":"G Aleppo","year":"2017","unstructured":"Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017;40(4):538\u201345.","journal-title":"Diabetes Care"},{"issue":"12","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrendo.2014.170","volume":"10","author":"BM Frier","year":"2014","unstructured":"Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711\u201322.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1177_CR19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc17-0636","volume":"40","author":"RW Beck","year":"2017","unstructured":"Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA. Diabetes Care. 2017;40(8):994\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"1177_CR20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2337\/dc17-1600","volume":"40","author":"T Danne","year":"2017","unstructured":"Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631\u201340.","journal-title":"Diabetes Care"},{"issue":"2","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/193229681300700234","volume":"7","author":"RM Bergenstal","year":"2013","unstructured":"Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7(2):562\u201378.","journal-title":"J Diabetes Sci Technol"},{"key":"1177_CR22","doi-asserted-by":"crossref","unstructured":"Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;1932296818822496.","DOI":"10.1177\/1932296818822496"},{"issue":"3","key":"1177_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400\u20135.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1177_CR24","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"Association AD","year":"2018","unstructured":"Association AD. 6. Glycemic targets. Diabetes Care. 2018;41(Suppl 1):S55\u201364.","journal-title":"Diabetes Care"},{"issue":"8","key":"1177_CR25","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2337\/dc14-2898","volume":"38","author":"IB Hirsch","year":"2015","unstructured":"Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610\u20134.","journal-title":"Diabetes Care"},{"issue":"8","key":"1177_CR26","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/dc15-0099","volume":"38","author":"RM Bergenstal","year":"2015","unstructured":"Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615\u201321.","journal-title":"Diabetes Care"},{"issue":"3","key":"1177_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.diabres.2014.06.007","volume":"105","author":"J Smith-Palmer","year":"2014","unstructured":"Smith-Palmer J, Br\u00e4ndle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273\u201384.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"1177_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1089\/dia.2012.0099","volume":"14","author":"Y Qu","year":"2012","unstructured":"Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14(11):1008\u201312.","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"1177_CR29","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1210\/jc.2012-1763","volume":"97","author":"MA Testa","year":"2012","unstructured":"Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. J Clin Endocrinol Metab. 2012;97(10):3504\u201314.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1177_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2337\/dc14-1801","volume":"38","author":"S Ayano-Takahara","year":"2015","unstructured":"Ayano-Takahara S, Ikeda K, Fujimoto S, Hamasaki A, Harashima SI, Toyoda K, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2015;38(1):e1\u20132.","journal-title":"Diabetes Care"},{"issue":"12","key":"1177_CR31","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00125-007-0820-z","volume":"50","author":"ES Kilpatrick","year":"2007","unstructured":"Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50(12):2553\u201361.","journal-title":"Diabetologia."},{"issue":"4","key":"1177_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2016.19976","volume":"317","author":"M Lind","year":"2017","unstructured":"Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379\u201387.","journal-title":"JAMA."},{"issue":"4","key":"1177_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/dia.2017.0363","volume":"20","author":"AF \u00d3lafsd\u00f3ttir","year":"2018","unstructured":"\u00d3lafsd\u00f3ttir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther. 2018;20(4):274\u201384.","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"1177_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jama.2016.19975","volume":"317","author":"RW Beck","year":"2017","unstructured":"Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371\u20138.","journal-title":"JAMA."},{"issue":"10057","key":"1177_CR35","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr\u00f6ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254\u201363.","journal-title":"Lancet."},{"issue":"11","key":"1177_CR36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S2213-8587(16)30193-0","volume":"4","author":"CA van Beers","year":"2016","unstructured":"van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893\u2013902.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10128","key":"1177_CR37","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(18)30297-6","volume":"391","author":"L Heinemann","year":"2018","unstructured":"Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367\u201377.","journal-title":"Lancet."},{"issue":"1","key":"1177_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/dia.2018.0257","volume":"21","author":"G Mulinacci","year":"2019","unstructured":"Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther. 2019;21(1):6\u201310.","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"1177_CR39","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.2337\/dc16-0207","volume":"39","author":"NC Foster","year":"2016","unstructured":"Foster NC, Miller KM, Tamborlane WV, Bergenstal RM, Beck RW, Network TDEC. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care. 2016;39(6):e81\u20132.","journal-title":"Diabetes Care"},{"issue":"9","key":"1177_CR40","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2213-8587(17)30217-6","volume":"5","author":"RW Beck","year":"2017","unstructured":"\u2022 Beck RW, Riddlesworth TD, Ruedy KJ, et al. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(9):700\u20138. Findings from this study suggest mixed results in those utilizing CGM who transition from MDI to CSII. The authors report statistically significant increased time in range, but also time spent in the hypoglycemic range <\u200970 mg\/dL and no statistically significant improvement in %CV.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1177_CR41","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1089\/dia.2016.0171","volume":"18","author":"J \u0160oupal","year":"2016","unstructured":"\u2022 \u0160oupal J, Petru\u017eelkov\u00e1 L, Fleka\u010d M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532\u20138. Findings from this study suggest CGM + MDI is superior to SMBG + CSII.","journal-title":"Diabetes Technol Ther"},{"key":"1177_CR42","doi-asserted-by":"crossref","DOI":"10.2337\/9781580404976","volume-title":"Putting your patients on the pump","author":"KM Bolderman","year":"2013","unstructured":"Bolderman KM, American Diabetes Association. Putting your patients on the pump. 2nd ed. Alexandria, VA: American Diabetes Association; 2013.","edition":"2"},{"issue":"11","key":"1177_CR43","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1210\/jc.2016-2534","volume":"101","author":"AL Peters","year":"2016","unstructured":"Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922\u201337.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1177_CR44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/1932296818766381","volume":"12","author":"AT Vesco","year":"2018","unstructured":"Vesco AT, Jedraszko AM, Garza KP, Weissberg-Benchell J. Continuous glucose monitoring associated with less diabetes-specific emotional distress and lower A1c among adolescents with type 1 diabetes. J Diabetes Sci Technol. 2018;12(4):792\u20139.","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"1177_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/dmrr.796","volume":"24","author":"BM Frier","year":"2008","unstructured":"Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24(2):87\u201392.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"1177_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2337\/diab.40.2.223","volume":"40","author":"SR Heller","year":"1991","unstructured":"Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40(2):223\u20136.","journal-title":"Diabetes."},{"issue":"8","key":"1177_CR47","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2337\/dc17-2682","volume":"41","author":"SA Little","year":"2018","unstructured":"Little SA, Speight J, Leelarathna L, Walkinshaw E, Tan HK, Bowes A, et al. Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: two-year follow-up in the HypoCOMPaSS randomized clinical trial. Diabetes Care. 2018;41(8):1600\u20137.","journal-title":"Diabetes Care"},{"issue":"11","key":"1177_CR48","doi-asserted-by":"publisher","first-page":"e113635","DOI":"10.1371\/journal.pone.0113635","volume":"9","author":"TW Lung","year":"2014","unstructured":"Lung TW, Hayes AJ, Herman WH, Si L, Palmer AJ, Clarke PM. A meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortality. PLoS One. 2014;9(11):e113635.","journal-title":"PLoS One"},{"key":"1177_CR49","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"4","key":"1177_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1002853","volume":"363","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"1177_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1303576","volume":"369","author":"RM Bergenstal","year":"2013","unstructured":"Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"1177_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/dia.2016.0421","volume":"19","author":"SK Garg","year":"2017","unstructured":"Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155\u201363.","journal-title":"Diabetes Technol Ther"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-019-1177-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T02:52:44Z","timestamp":1663815164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-019-1177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s11892-019-1177-7","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"27 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Christopher T. Martin reports consulting fees and stock from MicroOptx Inc. In addition, he is co-inventor of patent US20180333085A1 \u201cAqueous humor monitoring devices and methods\u201d pending to MicroOptx Inc.Amy B. Criego reports grants and other from Abbott Diabetes Care, other from Eli Lilly, grants from Medtronic, other from Senseonics, and grants from DexCom.Anders L. Carlson is employed by HealthPartners Institute\/Park Nicollet Health Services and they have contracts with Abbott, Medtronic, Dexcom, Novo Nordisk, Sanofi, and Insulet for his services as a research investigator and\/or consultant. No personal income from any of these services goes to Anders L. Carlson.Richard M. Bergenstal has received research support, consulted, or has been on the scientific advisory board for Abbott Diabetes Care, DexCom, Hygieia, Johnson & Johnson, Eli Lilly, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi, Senseonics, and United Healthcare. His employer, non-profit HealthPartners Institute, contracts for his services and no personal income goes to Richard M. Bergenstal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"50"}}